早产子痫前期高危孕妇的胎儿生长参数纵向变化
这项前瞻性纵向巢式病例对照研究纳入香港威尔士亲王医院2020年1月至2023年12月参加孕早期早产子痫前期筛查预防项目的单胎孕妇,比较低危未发生子痫前期、高危未发生子痫前期和高危发生子痫前期三组的胎儿生长参数、脐动脉搏动指数和羊水指数纵向变化,并分析其与孕早期生物标志物的相关性。结果显示三组间存在差异,高危发生子痫前期者孕中期多数胎儿生长参数Z评分较低且持续至晚孕期,羊水指数持续较低,脐动脉搏动指数孕中期最高、晚孕期下降但仍高于其他两组。
要点
- 高危发生子痫前期者孕中期多数胎儿生长参数Z评分显著低于其他两组,并持续至晚孕期。
- 高危妊娠羊水指数持续较低,发生子痫前期者两次随访间下降幅度最大。
- 高危发生子痫前期者孕中期脐动脉搏动指数Z评分最高,晚孕期下降但仍高于其他两组。
核心结论
- 基于孕早期筛查确定的早产子痫前期低危与高危孕妇之间,胎儿生长、脐动脉搏动指数和羊水指数存在差异,尤其在发生子痫前期的高危孕妇中;这些差异最早在孕中期即可见并持续至孕晚期,提示高危病例需要结构化的产前管理计划和胎儿监测,无论是否接受阿司匹林预防。
研究设计与样本
- 前瞻性纵向巢式病例对照研究,纳入香港威尔士亲王医院2020年1月至2023年12月参加孕早期早产子痫前期筛查预防项目的单胎孕妇,采用胎儿医学基金会孕早期三联试验评估风险,高危(校正风险≥1:100)者按母体体重每日服用阿司匹林100 mg或160 mg,于孕16周前开始并持续至孕36周或更早(分娩或发生子痫前期时),低危者按母体年龄、体重和入组日期匹配;共纳入509例未发生子痫前期的低危孕妇、1879例未发生子痫前期的高危孕妇和184例发生子痫前期的高危孕妇,于入组时测量平均动脉压、子宫动脉搏动指数和胎盘生长因子,并于孕20+0至24+6周和30+0至37+6周测量胎儿双顶径、头围、腹围、股骨长、估测胎儿体重、脐动脉搏动指数和羊水指数,采用多水平线性混合效应模型评估纵向变化,Pearson系数评估孕早期生物标志物与胎儿生长参数、脐动脉搏动指数和羊水指数的相关性。
诊断标准与关键数值
- 孕早期早产子痫前期高危定义为胎儿医学基金会三联试验校正风险≥1:100。
- 高危孕妇按母体体重每日服用阿司匹林100 mg或160 mg,于孕16周前开始并持续至孕36周或更早(分娩或发生子痫前期时)。
- 子宫动脉搏动指数与胎儿生长参数呈负相关,胎盘生长因子与胎儿生长参数呈正相关。
临床应用与阅片要点
- 对孕早期筛查确定为早产子痫前期高危的孕妇,即使接受阿司匹林预防,仍应关注孕中期至晚孕期胎儿生长参数、脐动脉搏动指数和羊水指数的纵向变化。
- 高危发生子痫前期者孕中期多数胎儿生长参数Z评分较低、羊水指数持续较低、脐动脉搏动指数孕中期最高,这些表现最早在孕中期出现并持续至孕晚期。
- 作者认为高危病例需要结构化的产前管理计划和胎儿监测,无论是否接受阿司匹林预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate longitudinal changes in fetal growth parameters, umbilical artery (UA) Doppler measurements and amniotic fluid index (AFI) in East Asian pregnant women who underwent screening for preterm pre-eclampsia (PE) in the first trimester, and to evaluate correlations of these variables with first-trimester biomarkers.
METHODS: This was a prospective, longitudinal, nested case-control study of women with a singleton pregnancy who participated in the first-trimester screen-and-prevent program for preterm PE at the Prince of Wales Hospital, Hong Kong SAR, China, between January 2020 and December 2023. The risk of developing preterm PE was determined using the Fetal Medicine Foundation first-trimester triple test. High-risk women (adjusted risk ≥ 1:100) were administered a daily dose of aspirin at either 100 mg or 160 mg according to maternal weight, starting before 16 weeks and continuing until 36 weeks' gestation, or earlier than 36 weeks in the case of delivery or development of PE. Low-risk women were matched based on maternal age, weight and the calendar date of enrolment. Biomarkers including mean arterial pressure, uterine artery (UtA) pulsatility index (PI) and placental growth factor (PlGF) were measured at the recruitment visit. Participants were followed up at 20 + 0 to 24 + 6 weeks and 30 + 0 to 37 + 6 weeks to measure fetal biparietal diameter, head circumference, abdominal circumference, femur length, estimated fetal weight, UA-PI and AFI. Multilevel linear mixed-effects modeling was used to assess longitudinal changes in fetal growth parameters, UA-PI and AFI. Pearson's coefficient was used to assess the correlation of first-trimester biomarkers with fetal growth parameters, UA-PI and AFI.
RESULTS: Our cohort comprised 509 low-risk women who did not develop PE, 1879 high-risk women who did not develop PE and 184 high-risk women who developed PE. At midgestation, mean Z-scores of most fetal growth parameters were significantly lower in the high-risk women who developed PE compared with those of the other groups. This pattern persisted into late gestation. AFI was consistently lower in high-risk pregnancies, with the greatest decrease between visits observed in those who developed PE. High-risk women who developed PE had the highest mean UA-PI Z-score at mid-gestation, which decreased by late gestation but remained elevated compared with the other two groups. UtA-PI was correlated negatively with fetal growth parameters, while PlGF showed a positive correlation with fetal growth parameters.
CONCLUSIONS: Differences in fetal growth, UA-PI and AFI exist between women identified as low vs high risk for preterm PE based on first-trimester screening, especially in high-risk women who develop PE. These findings are evident as early as the second trimester and persist into the third trimester. This highlights the need for a structured antenatal management plan with fetal monitoring in high-risk cases, irrespective of aspirin prophylaxis. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Yeung YK, Nguyen-Hoang L, Tse AW, et al. Longitudinal fetal growth parameters in women at high risk for pre-eclampsia. Ultrasound Obstet Gynecol. 2025. PMID: 40776726. doi:10.1002/uog.29313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。